Under OHIP+, access to new or innovative drugs for rare disorders is limited

Author:

Dr. Nigel Rawson

Insurance companies are the principal beneficiaries of Ontario’s new publicly-funded pharmacare program.Read more about Under OHIP+, access to new or innovative drugs for rare disorders is limitedTags: OHIP+pharmacarenew prescription drugsprescription drug innovationrare disorderspatientschildrenontariokathleen wynne

Read More - The Fraser Institute